Provider Briefing: Nisoldipine XR Availability in 2026

If you prescribe Nisoldipine XR (formerly brand Sular) for hypertension management, you've likely heard from patients struggling to fill their prescriptions. The supply situation for this dihydropyridine calcium channel blocker has been inconsistent for several years, and 2026 presents continued challenges.

This briefing covers the current supply landscape, prescribing considerations, therapeutic alternatives, and tools you can use to help your patients maintain uninterrupted blood pressure control.

Timeline: How We Got Here

Understanding the supply history helps contextualize the current situation:

• 2014: The FDA published a Federal Register determination confirming that brand Sular (Nisoldipine extended-release tablets in 10 mg, 20 mg, 25.5 mg, 30 mg, and 40 mg strengths) was not withdrawn from sale for reasons of safety or effectiveness. This cleared the path for generic ANDA approvals.
• Post-2014: Generic Nisoldipine ER became available from a limited number of manufacturers, most notably Emcure Pharmaceuticals USA, Inc. The reformulated hydrogel extended-release tablets (8.5 mg, 17 mg, 25.5 mg, 34 mg) became the primary available formulation.
• 2020-2025: Intermittent supply disruptions became increasingly common. With only a small number of generic manufacturers and declining prescription volumes, the supply chain became fragile.
• 2026: Nisoldipine XR continues to be manufactured but faces inconsistent availability at the pharmacy level. It is not consistently listed on the FDA Drug Shortage Database, creating a gap between official reporting and patient experience.

Prescribing Implications

The supply constraints for Nisoldipine XR create several clinical considerations:

Medication Adherence Risk

Patients who cannot readily fill their prescriptions are at elevated risk for missed doses or therapy discontinuation. Given that abrupt withdrawal of Nisoldipine can cause rebound hypertension or exacerbation of angina symptoms, this is a clinically significant concern.

Therapeutic Interchange Complexity

Nisoldipine has distinct pharmacokinetic properties within the dihydropyridine class, including:

• Low oral bioavailability (~5%) due to extensive first-pass metabolism
• Significant food interactions (grapefruit increases Cmax 3-7x; high-fat meals alter absorption)
• CYP3A4 substrate with notable interactions (phenytoin, rifampin, azole antifungals)
• Relatively potent vasodilation compared to other dihydropyridines

When converting to an alternative agent, dose equivalency is not straightforward. Individual titration is recommended.

Patient Communication

Patients taking Nisoldipine XR may not understand why their medication is difficult to find. Proactive communication about supply challenges — and reassurance that effective alternatives exist — can reduce anxiety and prevent self-discontinuation.

Current Availability Picture

As of early 2026, the availability of Nisoldipine XR can be characterized as follows:

• Manufacturing status: Generic Nisoldipine ER remains in active production by a limited number of manufacturers
• Pharmacy stocking: Many chain pharmacies do not carry Nisoldipine XR in regular inventory due to low demand. Independent and specialty pharmacies may have better access.
• Wholesaler availability: Intermittent. Supply may be available through some wholesalers but not others at any given time.
• Regional variation: Availability varies significantly by geography. Urban areas with more pharmacy options tend to have better access.

Cost and Access Considerations

Cost can be a barrier for patients, particularly those without insurance or with high-deductible plans:

• Retail cash price: $400-$530+ per 30-day supply (varies by strength)
• With discount cards: $130-$150 per 30-day supply (via GoodRx, SingleCare, etc.)
• Insurance coverage: Generic Nisoldipine is on many formularies at Tier 2 or Tier 3, but some plans may require prior authorization or step therapy through preferred agents (typically Amlodipine)
• No manufacturer assistance: With brand Sular discontinued, no manufacturer copay cards or patient assistance programs exist for Nisoldipine

For comparison, the cost differential with alternative agents is substantial: generic Amlodipine costs $4-$10/month, and generic Nifedipine ER costs $8-$20/month.

Tools and Resources for Providers

Several resources can help you support patients struggling with Nisoldipine XR access:

Pharmacy Availability Search

Medfinder for Providers allows you to search for pharmacies with Nisoldipine XR in stock near your patient's location. This can be used during the visit to identify a viable pharmacy before the patient leaves your office.

Patient Assistance Resources

While no manufacturer programs exist for Nisoldipine, patients with financial hardship may qualify for assistance through:

• NeedyMeds (needymeds.org) — searchable database of assistance programs
• RxAssist (rxassist.org) — comprehensive patient assistance directory
• State pharmaceutical assistance programs (SPAPs)

Therapeutic Alternatives Reference

When switching from Nisoldipine XR, consider these dihydropyridine CCB alternatives:

• Amlodipine (Norvasc): 2.5-10 mg daily. Most widely available and affordable. Longest half-life in class (30-50 hours). Less food interaction. First-line per ACC/AHA guidelines.
• Nifedipine ER (Procardia XL): 30-90 mg daily. Closest pharmacological profile to Nisoldipine. Also extended-release. Well-studied for hypertension and angina.
• Felodipine (Plendil): 2.5-10 mg daily. Similar vasoselectivity. Also has grapefruit interaction. Generic available.

For patients who cannot tolerate dihydropyridine CCBs, non-dihydropyridine options (Diltiazem, Verapamil) or other antihypertensive classes may be appropriate, depending on the clinical context.

Looking Ahead

The outlook for Nisoldipine XR availability depends largely on manufacturer investment and market dynamics. Given the trend toward prescribing more widely available CCBs, it is unlikely that new manufacturers will enter the Nisoldipine market in the near term.

For patients currently stable on Nisoldipine XR with reliable pharmacy access, there is no clinical reason to proactively switch. However, having an alternative plan documented in the patient's chart is prudent given the ongoing supply uncertainty.

For patients experiencing repeated fill difficulties, a proactive switch to a more readily available agent — with appropriate dose titration and monitoring — may be in the patient's best interest.

Final Thoughts

Nisoldipine XR remains a clinically effective antihypertensive, but supply constraints make it an increasingly impractical choice for new prescriptions. For existing patients, awareness of the availability challenges and a documented backup plan are key to preventing treatment gaps.

Medfinder for Providers can help you and your staff locate available pharmacies, and the therapeutic alternatives outlined above provide well-supported options for patients who need to transition to a more accessible medication.